Patent Application
20240033063
The present disclosure relates to a tubular structure.
There are cases in which a tubular structure having a lumen is inserted into the human body for the purpose of treatment or prevention. Representative examples include a vascular conduit or a vascular access (hemodialysis access) for dialysis.
In general, vascular conduits are artificial blood vessels that may be used to replace living blood vessels when there is a vascular disease that is difficult to cure by surgery or pharmacological treatment. However, since the vascular conduit is not a natural structure of the human body, various problems may arise. Representative problems are stenosis at a connection site between a vascular conduit and blood vessels of the human body and surrounding sites, thrombosis with stenosis, and an inflammatory reaction at the site of the vascular conduit. In order to solve these problems, studies have been conducted to prevent vascular stenosis and inflammation by forming a physiologically active substance layer or a drug layer in a vascular conduit.
However, since the effect of the drug on the inside or outside of the vascular conduit may vary depending on the type of drug layer, it is necessary to control this variation by a preferred method. In addition, since the properties of the vascular conduit may vary depending on the method of forming the drug layer, the development of a new technology considering this variation is required.
The technical spirit of the present disclosure is intended to solve the above-described problems, and an object of the technical spirit of the present disclosure is to provide a technology for a tubular structure that may be appropriately controlled to show different effects on the inside and outside of the vascular conduit depending on the type of drug.
Another object of the technical spirit of the present disclosure is to provide a technology for a tubular structure that is capable of appropriately controlling the drug release rate.
Objects to be achieved by the present invention are not limited to the above-mentioned objects, and other objects not mentioned herein will be dearly understood by those skilled in the art from the following description.
To achieve the above objects, as one embodiment of the present invention, a porous multi-layered tubular structure containing a physiologically active substance in pores includes a tubular structure in which a plurality of layers are stacked, wherein a plurality of pores are formed in each of the layers, and the physiologically active substance is contained in the pores of at least one of the layers.
In addition, the amount of the physiologically active substance contained in at least one of the layers may be different from the amount of the physiologically active substance contained in the other layer.
In addition, at least one of the layers may be formed to be different from the other layer in terms of the shape of the pores, the size of the pores, the arrangement of the pores, or the number of pores per unit area of the layer, so that the content of the physiologically active substance in the pores of each of the layers and the release rate of the physiologically active substance may be set differently for each of the layers.
In addition, the physiologically active substance may be a substance that inhibits cell proliferation or cell migration.
In addition, the physiologically active substance may be at least one selected from the group consisting of paclitaxel, rapamycin, and everolimus.
In addition, the content of the physiologically active substance in each of the layers may decrease in the direction from the innermost layer to the outermost layer of the tubular structure.
In addition, the outermost layer of the tubular structure may not contain the physiologically active substance.
In addition, when the physiologically active substance is paclitaxel, the content of the physiologically active substance per area of the innermost layer of the tubular structure may be 0.25 to 1.5 μg/mm2.
In addition, when the physiologically active substance is paclitaxel, the content of the physiologically active substance per area of the layer positioned next to the innermost layer of the tubular structure may be 0.25 to 0.75 μg/mm2.
In addition, the outermost layer of the tubular structure may not contain the physiologically active substance, or when the physiologically active substance is paclitaxel, the content of the physiologically active substance per area of the outermost layer may be 0.25 μg/mm2 or less.
In addition, the outermost layer of the tubular structure may have a smaller porosity than that of the other layer, as measured according to International Standardization Organization (ISO) standard 7198:1998, or a smaller number of pores than the other layer.
In addition, the outermost layer of the tubular structure may have a porosity of less than 25 μm as measured according to International Standardization Organization (ISO) standard 7198:1998.
In addition, the material of each of the layers may be at least any one selected from the group consisting of expanded polytetrafluoroethylene, polytetrafluoroethylene, and polyurethane.
In addition, the content of the physiologically active substance in each of the layers may decrease in the direction from the outermost layer to the innermost layer of the tubular structure.
In addition, when the tubular structure is formed of three or more layers, the porosity of a layer positioned next to the outermost layer of the tubular structure may be smaller than the porosities of the other layers, as measured according to International Standardization Organization (ISO) standard 7198:1998.
In addition, when the tubular structure is formed of three or more layers, the porosity of a layer positioned next to the outermost layer of the tubular structure may be less than 25 μm as measured according to International Standardization Organization (ISO) standard 7198:1998.
In addition, all of the plurality of layers may be formed of the same material.
In addition, when the tubular structure is formed of three layers, the porosity of a layer positioned between the outermost layer and the innermost layer of the tubular structure may be smaller than the porosities of the other layers.
In addition, when the tubular structure is formed of four or more layers, the porosity of any one of the layers excluding the outermost layer and the innermost layer of the tubular structure may be smaller than the porosities of the other layers.
The above-described technical solutions are merely illustrative and should not be construed as limiting the present invention. In addition to the exemplary embodiments described above, there may be additional embodiments described in the accompanying drawings and the detailed description of the invention.
As described above, according to various embodiments of the present invention, the content of the physiologically active substance may be set differently for each of the layers, and thus the release rate of the physiologically active substance in vivo may be appropriately controlled.
In addition, according to various embodiments of the present invention, the content of the physiologically active substance in each layer may decrease in the direction from the innermost layer to the outermost layer of the tubular structure, and the outermost layer may not contain the physiologically active substance, and thus it is possible to prevent the physiologically active substance from inhibiting proliferation of myofibroblasts outside of the vascular conduit.
In addition, according to various embodiments of the present invention, the size, number, shape, arrangement, etc. of pores may be different between layers, and thus the content of the physiologically active substance in the pores may be controlled differently for each of the layers. Thereby, it is possible to prevent a physiologically active substance that inhibits cell proliferation or cell migration from permeating from the inner circumferential surface to the outer circumferential surface of the tubular structure and reaching the outer circumferential surface.
In addition, according to the implementation, the content of the physiologically active substance in each layer may be controlled so that it decreases in the direction from the outermost layer to the innermost layer of the tubular structure and the innermost layer does not contain the physiologically active substance. Therefore, it is possible to selectively apply the physiologically active substance only to the outside of the tubular structure in consideration of the efficacy and type of physiologically active substance.
Effects according to various embodiments of the present invention are not limited to the above-mentioned effects, and other effects not mentioned herein will be dearly understood by those skilled in the art from the following description.
Preferred embodiments of the present invention will be described in more detail with reference to the accompanying drawings. The descriptions of already known technical features will be omitted or simplified for the sake of brevity.
It should be noted that references to “an” or “one” embodiment of the invention in this specification are not necessarily directed to the same embodiment, and they imply at least one.
In the following embodiments, terms such as “first” and “second” are not used in a limited sense, but are used for the purpose of distinguishing one component from another component.
In the following examples, singular expressions include plural expressions unless the context dearly indicates otherwise.
In the following embodiments, terms such as “include” and “have” are intended to denote the presence of mentioned features or components, but do not exclude the probability of presence or addition of one or more other features or components.
In the following embodiments, when a part, such as a layer, region, component, or the like, is referred to as being “on” or “above” another part, it not only refers to a case where the part may be directly above the other part, but also a case where a third part exists therebetween.
Sizes, heights, thicknesses, and the like in the drawings referred to when describing the embodiments of the present disclosure may be intentionally exaggerated and expressed for convenience of description and to facilitate understanding, and are not enlarged or shrunk according to any ratio. In addition, some elements illustrated in the drawings may be intentionally expressed as being smaller, and the other elements may be intentionally expressed as being larger.
In the first embodiment, a plurality of pores may be formed in each of the layers constituting the tubular structure 10. According to the first embodiment, a plurality of pores may be formed in the first layer 110, the second layer 120, and the third layer 130. In addition, a physiologically active substance may be contained in at least one pore in at least one of the layers.
In the first embodiment, the physiologically active substance refers to a substance that inhibits cell proliferation or cell migration. For example, the physiologically active substance may be at least one selected from the group consisting of paclitaxel, rapamycin, and everolimus.
According to the first embodiment, the porosity of the pores 111 and 112 formed in the first layer 110 among the plurality of layers may be different from the porosity of the pores 121 formed in the second layer 120. That is, by making the porosity different between the layers, it is possible to control the content of the physiologically active substance in the pores 111 and 112 of the first layer 110 so as to be different from the content of the physiologically active substance in the pores 121 of the second layer 120. As used herein, the term “porosity” means a microscopic porosity value measured according to International Organization Standardization (ISO) standard 7198:1998
As a specific example, in the first embodiment, the porosity of the pores 111 and 112 formed in the first layer 110 among the three layers may be larger than that of the pores 121 formed in the second layer 120, and the porosity of the pores 131 and 132 formed in the third layer 130 may be smaller than that of the pores 121 formed in the second layer 120. Thus, the content of the physiologically active substance in each pore decreases in the direction from the first layer 110 to the third layer 130. In addition, the porosity of each layer may be controlled so that the pores 131 and 132 of the third layer 130 do not contain the physiologically active substance, unlike the first layer 110 or the second layer 120.
According to the first embodiment, the shape, size, or arrangement of the pores 111 and 112 formed in the first layer 110 among the plurality of layers constituting the tubular structure 10, or the number of the pores 111 and 112 per unit area of the first layer, may be different from the shape, size, or arrangement of the pores 121 formed in the second layer 120, or the number of pores 121 per unit area of the second layer. That is, when the shape, size, arrangement of pores or the number of pores per unit area of each layer is set differently for each of the layers, the content of the physiologically active substance in the pores 111 and 112 of the first layer 110 may be different from the content of the physiologically active substance in the pores 121 of the second layer 120.
As a specific example, when 30 pores are formed in the first layer 110, 20 pores are formed in the second layer 120, and 10 pores are formed in the third layer 130, the content of the physiologically active substance in the pores will be different between the layers. In addition, at least any one of the number, shape, and arrangement of the pores may be controlled so that the physiologically active substance is not contained in the pores 131 and 132 of the third layer 130.
According to the first embodiment, the content of the physiologically active substance per area of the first layer 110, which is the innermost layer of the tubular structure 10, is 0.25 to 1.5 μg/mm2 regardless of the thickness of the layer, when the physiologically active substance is paclitaxel. As a specific example, the content of the physiologically active substance per area of the first layer 110 may be 0.25 μg/mm2, 0.35 μg/mm2, 0.45 μg/mm2, 0.55 μg/mm2, 0.65 μg/mm2, 0.75 μg/mm2, 0.85 μg/mm2, 0.95 μg/mm2, 1.05 μg/mm2, 1.15 μg/mm2, 1.25 μg/mm2, 1.35 μg/mm2, 1.45 μg/mm2, or 1.5 μg/mm2 regardless of the thickness of the layer, when the physiologically active substance is paclitaxel. In addition, the content of the physiologically active substance per area of the first layer 110 may range from a value equal to or greater than any one of the above values to a value equal to or smaller than any one of the above values.
For example, the content of the physiologically active substance per area of the first layer 110 may be in the range of 0.25 μg/mm2 to 1.5 μg/mm2, 0.35 μg/mm2 to 1.45 μg/mm2, 0.55 μg/mm2 to 1.35 μg/mm2, 0.65 μg/mm2 to 1.25 μg/mm2, 0.75 μg/mm2 to 1.15 μg/mm2, or 0.85 μg/mm2 to 1.05 μg/mm2 regardless of the thickness of the layer, when the physiologically active substance is paclitaxel.
According to the first embodiment, the content of the physiologically active substance per area of the second layer 120 stacked on the outer circumferential surface of the first layer 110 may be 0.25 to 0.75 μg/mm2 regardless of the thickness of the layer, when the physiologically active substance is paclitaxel. As a specific example, the content of the physiologically active substance per area of the second layer 120 may be 0.25 μg/mm2, 0.35 μg/mm2, 0.45 μg/mm2, 0.55 μg/mm2, 0.65 μg/mm2 or 0.75 μg/mm2 regardless of the thickness of the layer, when the physiologically active substance is paclitaxel. In addition, the content of the physiologically active substance per area of the second layer 120 may range from a value equal to or greater than any one of the above values to a value equal to or smaller than any one of the above values.
For example, the content of the physiologically active substance per area of the second layer 120 may be in the range of 0.25 μg/mm2 to 0.75 μg/mm2, 0.35 μg/mm2 to 0.65 μg/mm2, or 0.45 μg/mm2 to 0.55 μg/mm2 regardless of the thickness of the layer, when the physiologically active substance is paclitaxel.
Meanwhile, according to the implementation, the third layer 130, which is the outermost layer of the tubular structure 10, may contain the physiologically active substance in a smaller amount than the first layer 110 or the second layer 120 (for example, when the physiologically active substance is paclitaxel, the content of the physiologically active substance in the third layer may be 0.01 to 0.25 μg/mm2 regardless of the thickness of the layer).
According to the first embodiment, the third layer 130, which is the outermost layer of the tubular structure 10, may be formed so that the porosity of the pores 131 and 132 is smaller than those of the other layers. In addition, the third layer 130 may be formed so that the number of pores 131 and 132 is smaller than those in the other layers. Thereby, the third layer 130 may not contain the physiologically active substance at all or may contain the physiologically active substance in a smaller amount than the other layers.
The tubular structure 10 according to the first embodiment has a plurality of layers, wherein the average size of pores formed in each of the layers may be 0.1 μm to less than 25 μm as measured according to International Standardization Organization (ISO) standard 7198.
In the first embodiment, the material of each of the layers constituting the tubular structure 10 may be at least one selected from the group consisting of expanded polytetrafluoroethylene, polytetrafluoroethylene, and polyurethane. Meanwhile, according to the implementation, all of the plurality of layers may be formed of the same material. In one embodiment, when all of the layers constituting the multi-layered tubular structure are formed of the same material, the elasticity and ductility of each layer may be equal between the layers, and it is possible to prevent the adjacent layers from falling off or cracking when the tubular structure is bent by an external force.
The tubular structure 10 according to the first embodiment may be manufactured by spraying a mixed solution of a polar solvent, a non-polar solvent and a physiologically active substance toward the inner circumferential surface of the first layer 110 in a state in which the first layer 110, the second layer 120 and the third layer 130 are stacked in advance. That is, it may be manufactured by positioning a spraying device inside the tubular structure 10 and spraying the solution toward the inner circumferential surface of the first layer 110.
In the second embodiment, a plurality of pores may be formed in each of the layers constituting the tubular structure 20. According to the second embodiment, a plurality of pores may be formed in the first layer 210, the second layer 220, the third layer 230 and the fourth layer 240. In addition, a physiologically active substance may be contained in at least one pore in at least one of the layers.
In the second embodiment, the physiologically active substance may be applied in the same way as in the first embodiment. According to the second embodiment, the porosity of the pores 211, 212, and 213 formed in the first layer 210 among the plurality of layers may be different from the porosity of the pores 221 formed in the second layer 220. That is, by making the porosity of the pores different between the layers, it is possible to control the content of the physiologically active substance in the pores 211, 212 and 213 of the first layer 210 so as to be different from the content of the physiologically active substance in the pores 221 of the second layer 220.
As a specific example, in the second embodiment, the porosity of the pores 211, 212 and 213 formed in the first layer 210 among the four layers may be larger than the porosity of the pores 221 formed in the second layer 220, the porosity of the pores 221 formed in the second layer 220 may be larger than that of the pores 231 and 232 formed in the third layer 230, and the porosity of the pores 231 and 232 formed in the third layer 230 may be larger than that of the pores 241 formed in the fourth layer 240. Thus, the content of the physiologically active substance in each pore decreases in the direction from the first layer 210 toward the fourth layer 240. In addition, it is possible to control the porosity of the pores so that the pores 241 of the fourth layer 240 do not contain the physiologically active substance, unlike the first layer 210, the second layer 220 and the third layer 230.
According to the second embodiment, the shape, size, or arrangement of the pores 211, 212 and 213 formed in the first layer 210 among the plurality of layers constituting the tubular structure 20, or the number of the pores 211, 212 and 213 per unit area of the first layer, may be different from the shape, size, or arrangement of the pores 221 formed in the second layer 220, or the number of pores 221 per unit area of the second layer. That is, when the shape, size, arrangement of pores or the number of pores per unit area of each layer is set differently for each of the layers, the content of the physiologically active substance in the pores 211, 212 and 213 of the first layer 210 may be different from the content of the physiologically active substance in the pores 221 of the second layer 220.
As a specific example, when 30 pores are formed in the first layer 210, 20 pores are formed in the second layer 220, 10 pores are formed in the third layer 230, and 5 pores are formed in the fourth layer 240, the content of the physiologically active substance in the pores will be different between the layers. In addition, at least any one of the number, shape, and arrangement of the pores may be controlled so that the physiologically active substance is not contained in the pores 241 of the fourth layer 240.
According to the second embodiment, the content of the physiologically active substance per area of the first layer 210, which is the innermost layer of the tubular structure 20, may be 0.25 to 1.5 μg/mm2. As a specific example, the content of the physiologically active substance per area of the first layer 210 may be 0.25 μg/mm2, 0.35 μg/mm2, 0.45 μg/mm2, 0.55 μg/mm2, 0.65 μg/mm2, 0.75 μg/mm2, 0.85 μg/mm2, 0.95 μg/mm2, 1.05 μg/mm2, 1.15 μg/mm2, 1.25 μg/mm2, 1.35 μg/mm2, 1.45 μg/mm2, or 1.5 μg/mm2 regardless of the thickness of the layer, when the physiologically active substance is paclitaxel. In addition, the content of the physiologically active substance per area of the first layer 210 may range from a value equal to or greater than any one of the above values to a value equal to or smaller than any one of the above values.
For example, the content of the physiologically active substance per area of the first layer 210 may be in the range of 0.25 μg/mm2 to 1.5 μg/mm2, 0.35 μg/mm2 to 1.45 μg/mm2, 0.55 μg/mm2 to 1.35 μg/mm2, 0.65 μg/mm2 to 1.25 μg/mm2, 0.75 μg/mm2 to 1.15 μg/mm2, or 0.85 μg/mm2 to 1.05 μg/mm2 regardless of the thickness of the layer, when the physiologically active substance is paclitaxel.
According to the second embodiment, the content of the physiologically active substance per area of the second layer 220 attached to the outer circumferential surface of the first layer 210 may be 0.25 to 0.75 μg/mm2 regardless of the thickness of the layer, when the physiologically active substance is paclitaxel. As a specific example, the content of the physiologically active substance per area of the second layer 220 may be 0.25 μg/mm2, 0.35 μg/mm2, 0.45 μg/mm2, 0.55 μg/mm2, 0.65 μg/mm2 or 0.75 μg/mm2 regardless of the thickness of the layer, when the physiologically active substance is paclitaxel. In addition, the content of the physiologically active substance per area of the second layer 220 may range from a value equal to or greater than any one of the above values to a value equal to or smaller than any one of the above values.
For example, the content of the physiologically active substance per area of the second layer 220 may be in the range of 0.25 μg/mm2 to 0.75 μg/mm2, 0.35 μg/mm2 to 0.65 μg/mm2, or 0.45 μg/mm2 to 0.55 μg/mm2 regardless of the thickness of the layer, when the physiologically active substance is paclitaxel.
Meanwhile, according to the implementation, the fourth layer 240, which is the outermost layer of the tubular structure 20, may contain the physiologically active substance in a smaller amount than the other layers (for example, when the physiologically active substance is paclitaxel, the content of the physiologically active substance in the fourth layer may be 0.01 to 0.25 μg/mm2 regardless of the thickness of the layer).
According to the second embodiment, the fourth layer 240, which is the outermost layer of the tubular structure 20, may be formed so that the porosity of the pores 241 is smaller than those of the other layers. In addition, the fourth layer 240 may be formed so that the number of the pores 241 is smaller than those in the other layers. Thereby, the fourth layer 240 may not contain the physiologically active substance at all or may contain the physiologically active substance in a smaller amount than the other layers.
The tubular structure 20 according to the second embodiment has a plurality of layers, wherein the average size of pores formed in each of the layers may be 0.1 μm to less than 25 μm as measured according to International Standardization Organization (ISO) standard 7198.
In the second embodiment, the material of each of the layers constituting the tubular structure 20 may be as described above with respect to the first embodiment.
The tubular structure 20 according to the second embodiment may be manufactured by spraying a mixed solution of a polar solvent, a non-polar solvent and a physiologically active substance toward the inner circumferential surface of the first layer 210 in a state in which the first layer 210, the second layer 220, the third layer 230 and the fourth layer 240 are stacked in advance. That is, it may be manufactured by positioning a spraying device inside the tubular structure 10 and spraying the solution toward the inner circumferential surface of the first layer 110.
In the third embodiment, a plurality of pores may be formed in each of the layers constituting the tubular structure 30. According to the third embodiment, a plurality of pores may be formed in the first layer 310, the second layer 320, and the third layer 330. In addition, a physiologically active substance may be contained in at least one pore in at least one of the layers.
In the third embodiment, the physiologically active substance may be of a type different from that in the first embodiment. For example, the physiologically active substance according to the third embodiment may be an anti-inflammatory agent. In the case in which it is preferable in terms of the efficacy of the physiologically active substance that the physiologically active substance be contained in an outer layer of the tubular structure 30 rather than contained in an inner layer of the tubular structure 30, control may be made so that the physiologically active substance is selectively applied only to the outer layer without existing in the inner layer of the tubular structure 30.
According to the third embodiment, the porosity of the pores 311 and 312 formed in the first layer 310 among the plurality of layers may be different from the porosity of the pores 321 formed in the second layer 320. That is, by making the porosity of the pores different between the layers, it is possible to control the content of the physiologically active substance in the pores 311 and 312 of the first layer 310 so as to be different from the content of the physiologically active substance in the pores 321 of the second layer 320.
As a specific example, in the third embodiment, the porosity of the pores 331 and 332 formed in the third layer 330 among the three layers may be larger than that of the pores 321 formed in the second layer 320, and the porosity of the pores 321 formed in the second layer 320 may be larger than that of the pores 311 and 312 in the first layer 310. Thus, the content of the physiologically active substance in the pores of each layer decreases in the direction from the third layer 330, which is the outermost layer of the tubular structure 30, toward the first layer 310 which is the innermost layer. In addition, the porosity of the pores may be controlled so that the pores 311 and 312 of the first layer 310 do not contain the physiologically active substance, unlike the second layer 320 or the third layer 330.
According to the third embodiment, the shape, size, or arrangement of the pores 311 and 312 formed in the first layer 310 among the plurality of layers constituting the tubular structure 30, or the number of the pores 311 and 312 per unit area of the first layer, may be different from the shape, size, or arrangement of the pores 321 formed in the second layer 320, or the number of the pores 321 per unit area of the second layer. That is, when the shape, size, arrangement of pores or the number of pores per unit area of each layer is set differently for each of the layers, the content of the physiologically active substance in the pores 311 and 312 of the first layer 310 may be different from the content of the physiologically active substance in the pores 321 of the second layer 320.
According to the third embodiment, the first layer 310, which is the innermost layer of the tubular structure 30, may be formed so that the porosity of the pores 311 and 312 is smaller than those of the other layers. In addition, the first layer 310 may be formed so that the number of the pores 311 and 312 is smaller than those in the other layers. Thereby, the first layer 310 may not contain the physiologically active substance at all or may contain the physiologically active substance in a smaller amount than the other layers.
In the third embodiment, the material of each of the layers constituting the tubular structure 30 may be as described above with respect to the first embodiment.
The tubular structure 30 according to the third embodiment may be manufactured by spraying a mixed solution of a polar solvent, a non-polar solvent and a physiologically active substance toward the outer circumferential surface of the third layer 330 in a state in which the first layer 310, the second layer 320 and the third layer 330 are stacked in advance. That is, it may be manufactured by positioning a spraying device outside the tubular structure 30 and spraying the solution toward the outer circumferential surface of the third layer.
In the fourth embodiment, a plurality of pores may be formed in each of the layers constituting the tubular structure 40. According to the fourth embodiment, a plurality of pores may be formed in the first layer 410, the second layer 420, the third layer 430 and the fourth layer 440. In addition, a physiologically active substance may be contained in at least one pore in at least one of the layers.
In the fourth embodiment, the physiologically active substance may be of a type different from that in the first embodiment. For example, the physiologically active substance according to the fourth embodiment may be an anti-inflammatory agent. In the case in which it is preferable in terms of the efficacy of the physiologically active substance that the physiologically active substance be contained in an outer layer of the tubular structure 40 rather than contained in an inner layer of the tubular structure 40, control may be made so that the physiologically active substance is selectively applied only to the outer layer without existing in the inner layer of the tubular structure 40.
According to the fourth embodiment, the porosity of the pores 411 formed in the first layer 410 among the plurality of layers may be different from the porosity of the pores 421 formed in the second layer 420. That is, by making the porosity of the pores different between the layers, it is possible to control the content of the physiologically active substance in the pores 411 of the first layer 410 so as to be different from the content of the physiologically active substance in the pores 421 of the second layer 420.
As a specific example, in the fourth embodiment, the porosity of the pores 441 and 443 formed in the fourth layer 440 among the four layers may be larger than the porosity of the pores 431 and 432 formed in the third layer 430, the porosity of the pores 431 and 432 formed in the third layer 430 may be larger than the porosity of the pores 421 formed in the second layer 420, and the porosity of the pores 421 formed in the second layer 420 may be larger than the porosity of the pores 411 formed in the first layer 410. Thus, the content of the physiologically active substance in the pores of each layer decreases in the direction from the fourth layer 440, which is the outermost layer of the tubular structure 40, toward the first layer 410 which is the innermost layer. In addition, the porosity of the pores may be controlled so that the pores 411 of the first layer 410 do not contain the physiologically active substance, unlike the second layer 420, the third layer 430 and the fourth layer 440.
According to the fourth embodiment, the shape, size, or arrangement of the pores 411 formed in the first layer 410 among the plurality of layers constituting the tubular structure 40, or the number of the pores 411 per unit area of the first layer, may be different from the shape, size, or arrangement of the pores 421 formed in the second layer 420, or the number of the pores 421 per unit area of the second layer. That is, when the shape, size, arrangement of pores or the number of pores per unit area of each layer is set differently for each of the layers, the content of the physiologically active substance in the pores 411 of the first layer 410 may be different from the content of the physiologically active substance in the pores 421 of the second layer 420.
Meanwhile, according to the implementation, the first layer 410, which is the innermost layer of the tubular structure 40, may also contain the physiologically active substance in a smaller amount than the other layers.
According to the fourth embodiment, the first layer 410, which is the innermost layer of the tubular structure 40, may be formed so that the porosity of the pores 411 is smaller than those of the other layers. In addition, the first layer 410 may be formed so that the number of the pores 411 is smaller than those in the other layers. Thereby, the first layer 410 may not contain the physiologically active substance at all or may contain the physiologically active substance in a smaller amount than the other layers.
In the fourth embodiment, the material of each of the layers constituting the tubular structure 40 may be as described above with respect to the first embodiment.
In another embodiment, when the tubular structure is formed of three or more layers, the porosity of a layer positioned next to the outermost layer of the tubular structure may be smaller than the porosities of the other layers. In another embodiment, when the tubular structure is formed of three or more layers, the porosity of a layer positioned next to the outermost layer of the tubular structure may be 0.1 μm to less than 25 μm. Accordingly, the innermost layer or the outermost layer of the tubular structure may not contain the physiologically active substance at all or may contain the physiologically active substance in very small amounts.
That is, a first layer 510 is the innermost layer of the tubular structure 50. A second layer 520 is attached to the outer circumferential surface of the first layer 510, and a third layer 530 is attached to the outer circumferential surface of the second layer 520. The third layer 530 is the outermost layer of the tubular structure 50.
In the fifth embodiment, a plurality of pores may be formed in each of the layers constituting the tubular structure 50. According to the fifth embodiment, a plurality of pores may be formed in the first layer 510, the second layer 520, and the third layer 530. In addition, a physiologically active substance may be contained in at least one pore in at least one of the layers. In the fifth embodiment, the physiologically active substance may be of the same or different type as that in the first embodiment.
According to the fifth embodiment, when the tubular structure 50 is formed of three layers, the second layer 520 positioned between the third layer 530, which is the outermost layer of the tubular structure 50, and the first layer 510 which is the innermost layer, may have the smallest porosity.
In the fifth embodiment, the material of each of the layers constituting the tubular structure 50 may be as described above with respect to the first embodiment.
That is, a first layer 610 is the innermost layer of the tubular structure 60. A second layer 620 is attached to the outer circumferential surface of the first layer 610, a third layer 630 is attached to the outer circumferential surface of the second layer 620, and a fourth layer 640 is attached to the outer circumferential surface of the third layer 630. The fourth layer 640 is the outermost layer of the tubular structure 60.
In the sixth embodiment, a plurality of pores may be formed in each of the layers constituting the tubular structure 60. According to the sixth embodiment, a plurality of pores may be formed in the first layer 610, the second layer 620, the third layer 630, and the fourth layer 640. In addition, a physiologically active substance may be contained in at least one pore in at least one of the layers. In the sixth embodiment, the physiologically active substance may be of the same or different type as that in the first embodiment.
In one embodiment, when the tubular structure is formed of four or more layers, any one of the layers excluding the outermost layer and the innermost layer of the tubular structure may have the smallest porosity.
According to the sixth embodiment, when the tubular structure 60 is formed of four layers, the second layer 620 positioned between the fourth layer 640, which is the outermost layer of the tubular structure 60, and the first layer 610 which is the innermost layer, may have the smallest porosity.
In the sixth embodiment, the material of each of the layers constituting the tubular structure 60 may be as described above with respect to the first embodiment.
That is, a first layer 710 is the innermost layer of the tubular structure 70. A second layer 720 is attached to the outer circumferential surface of the first layer 710, a third layer 730 is attached to the outer circumferential surface of the second layer 720, and a fourth layer 740 is attached to the outer circumferential surface of the third layer 730. The fourth layer 740 is the outermost layer of the tubular structure 70.
In the seventh embodiment, a plurality of pores may be formed in each of the layers constituting the tubular structure 70. According to the seventh embodiment, a plurality of pores may be formed in the first layer 710, the second layer 720, the third layer 730, and the fourth layer 740. In addition, a physiologically active substance may be contained in at least one pore in at least one of the layers. In the seventh embodiment, the physiologically active substance may be of the same or different type as that in the first embodiment.
According to the seventh embodiment, when the tubular structure 70 is formed of four layers, the third layer 730 positioned between the fourth layer 740, which is the outermost layer of the tubular structure 70, and the first layer 710 which is the innermost layer, may have the smallest porosity.
In the seventh embodiment, the material of each of the layers constituting the tubular structure 70 may be as described above with respect to the first embodiment.
According to one embodiment, in the case in which any one layer positioned between the outermost layer and the innermost layer of the tubular structure has the smallest porosity, when a syringe needle penetrates the surface of the tubular structure and then the needle is removed, the puncture point of the layer having the smallest porosity may easily shrink, thereby preventing leakage.
According to another embodiment, the outermost layer of the tubular structure may have a larger porosity than any one of the layers excluding the outermost layer and the innermost layer of the tubular structure. In this case, the outermost layer of the tubular structure may maintain a certain porosity, and thus skin tissue may easily penetrate into the pores of the outermost layer, which is in direct contact with the skin, and the tight coupling between the tubular structure and the skin may occur, so that the tubular structure may be stably maintained in vivo without departing from the initial placement position.
As described above, according to various embodiments of the present invention, the content of the physiologically active substance may be set differently between the layers, and thus the release rate of the physiologically active substance in vivo may be appropriately controlled.
In addition, according to various embodiments of the present invention, as the content of the physiologically active substance in each layer decreases in the direction from the innermost layer to the outermost layer of the tubular structure, and the outermost layer does not contain the physiologically active substance, it is easy for myofibroblasts to proliferate outside of the vascular conduit.
In addition, according to various embodiments of the present invention, as the size, number, shape, arrangement, etc. of pores are set differently for each of the layers, the content of the physiologically active substance in the pores and the release rate thereof may be controlled differently for each of the layers. Thereby, it is possible to prevent a physiologically active substance (e.g., paclitaxel, rapamycin, everolimus, etc.) that inhibit cell proliferation or cell migration from permeating from the inner circumferential surface to the outer circumferential surface of the tubular structure and reaching the outer circumferential surface. In addition, even when a liquid mixture of a physiologically active substance and an organic solvent is applied to the tubular structure, it is possible to prevent the organic solvent from reaching the outer circumferential surface of the tubular structure and deforming or damaging the outer circumferential surface of the tubular structure, thereby preventing unexpected side effects from occurring in vivo.
In addition, according to the implementation, the content of the physiologically active substance in each layer may controlled so that it decreases in the direction from the outermost layer of the tubular structure toward to the innermost layer and the innermost layer does not contain the physiologically active substance. Accordingly, in consideration of the efficacy and type of physiologically active substance, control may be made so that a physiologically active material (e.g., an anti-inflammatory agent) is selectively applied only to the outside of the tubular structure.
Although the specific description of the present invention has been given in conjunction with the embodiments described with reference to the accompanying drawings, the above-described embodiments are only preferred examples of the present invention. Therefore, the present invention should not be construed as being limited only to the above-described embodiments, and the scope of the present invention should be defined based on the following claims and equivalents thereto.
| Number | Date | Country | Kind |
|---|---|---|---|
| 10-2020-0108913 | Aug 2020 | KR | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/KR2021/010543 | 8/10/2021 | WO |
